82 FR 60199 - Agency Forms Undergoing Paperwork Reduction Act Review

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention

Federal Register Volume 82, Issue 242 (December 19, 2017)

[Federal Register Volume 82, Number 242 (Tuesday, December 19, 2017)]
[Notices]
[Pages 60199-60200]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2017-27257]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[30Day-18-17AMP]


Agency Forms Undergoing Paperwork Reduction Act Review

    In accordance with the Paperwork Reduction Act of 1995, the Centers 
for Disease Control and Prevention (CDC) has submitted the information 
collection request titled Evaluation of the SAMHSA Naloxone Education 
and Distribution Program to the Office of Management and Budget (OMB) 
for review and approval. CDC previously published a ``Proposed Data 
Collection Submitted for Public Comment and Recommendations'' notice on 
July 17, 2017 to obtain comments from the public and affected agencies. 
CDC did not receive comments related to the previous notice. This 
notice serves to allow an additional 30 days for public and affected 
agency comments.
    CDC will accept all comments for this proposed information 
collection project. The Office of Management and Budget is particularly 
interested in comments that:
    (a) Evaluate whether the proposed collection of information is 
necessary for the proper performance of the functions of the agency, 
including whether the information will have practical utility;
    (b) Evaluate the accuracy of the agencies estimate of the burden of 
the proposed collection of information, including the validity of the 
methodology and assumptions used;
    (c) Enhance the quality, utility, and clarity of the information to 
be collected;
    (d) Minimize the burden of the collection of information on those 
who are to respond, including, through the use of appropriate 
automated, electronic, mechanical, or other technological collection 
techniques or other forms of information technology, e.g., permitting 
electronic submission of responses; and
    (e) Assess information collection costs.
    To request additional information on the proposed project or to 
obtain a copy of the information collection plan and instruments, call 
(404) 639-7570 or send an email to [email protected]. Direct written comments 
and/or suggestions regarding the items contained in this notice to the 
Attention: CDC Desk Officer, Office of Management and Budget, 725 17th 
Street NW, Washington, DC 20503 or by fax to (202) 395-5806. Provide 
written comments within 30 days of notice publication.

Proposed Project

    Evaluation of the SAMHSA Naloxone Education and Distribution 
Program--New--National Center for Injury Prevention and Control 
(NCIPC), Centers for Disease Control and Prevention (CDC).

Background and Brief Description

    Overdose deaths involving prescription opioids and heroin have 
reached epidemic levels in the U.S. and continue to rise. To address 
the prescription drug/opioid overdose crisis, the federal government 
has recently allocated funding to improve access to treatment for 
opioid use disorders, reduce opioid related deaths, and strengthen 
prevention efforts. One program resulting from the federal government's 
efforts to address the opioid crisis is the Substance Abuse and Mental 
Health Services Agency (SAMHSA) Grants to Prevent Prescription Drug/
Opioid Overdose-Related Deaths. This proposed information collection 
project will help evaluate this program.
    Through this program, SAMHSA awarded funding to 12 states. The 
funding is aimed at reducing the number of prescription drug/opioid 
overdose-related deaths and adverse events among individuals 18 years 
of

[[Page 60200]]

age and older through educating and training first responders and other 
key community sectors on the prevention of prescription drug/opioid 
overdose-related deaths, including the purchase and distribution of 
naloxone. SAMHSA is funding the grant and CDC is responsible for 
conducting the grantee evaluation.
    The intended use of the resulting data is to increase CDC and 
SAMHSA understanding of the scope and impact of the program on overdose 
fatalities and how program effectiveness may vary among different sub-
populations and settings, and to increase knowledge of barriers and 
facilitators to program implementation.
    Researchers will use key informant interviews and focus groups with 
participants in the activities enacted by the twelve state grant 
recipients. Participants will include state administrators of the grant 
and other PDO/Naloxone stakeholders including advisory council members, 
first responders, social service providers, laypersons including end 
users and their family and friend. All focus groups and interviews will 
be analyzed through qualitative content analysis, including utilization 
of a systematic coding scheme.
    Total burden in hours for this collection is 381. There are no 
costs to respondents other than their time. CDC requests a three-year 
OMB approval to collect the necessary project-related information.

                                        Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
                                                                                     Number of    Average burden
          Type of respondents                   Form name            Number of     responses per   per response
                                                                    respondents     respondent      (in hours)
----------------------------------------------------------------------------------------------------------------
PDO/Naloxone Advisory Committee         Focus Group Discussion               140               1             1.5
 Members and Grantees.                   Guide.
PDO/Naloxone Grantees.................  Key Informant Interview               36               1               1
                                         Guide for Grantees.
PDO/Naloxone Stakeholders and Partners  Key Informant Interview               84               1               1
                                         Guide for Partners.
PDO/Naloxone Laypersons...............  Key Informant Interview               24               1               1
                                         Guide for Laypersons.
All participants (PDO Naloxone          Recruitment contact                  284               1            5/60
 grantees, advisory committee,           script.
 stakeholders and partners,
 laypersons).
PDO/Naloxone Grantees.................  Key Informant Selection               12               1           15/60
                                         Tool.
----------------------------------------------------------------------------------------------------------------


Leroy A. Richardson,
Chief, Information Collection Review Office, Office of Scientific 
Integrity, Office of the Associate Director for Science, Office of the 
Director, Centers for Disease Control and Prevention.
[FR Doc. 2017-27257 Filed 12-18-17; 8:45 am]
 BILLING CODE 4163-18-P